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RESEARCH ARTICLE
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Abstract
Zika virus (ZIKV) emerged as a global public health threat throughout the Americas over the
last six years. Phylogenetically, the virus is composed of three main lineages, an African,
Asian, and American lineage. The recent emergence and spread of ZIKV has raised ques-
tions regarding the breadth and potency of human primary ZIKV immune sera against anti-
genically diverse ZIKV. Although ZIKV is thought to compose a single antigenic serotype, in-
depth evaluation of the antigenic relatedness of ZIKV across genetic variants has been lim-
ited to a relatively small series of early convalescent human immune sera (4–12 weeks)
against a limited number (3) of genetic variants. Using virus neutralization assays, we char-
acterize the potency and breadth of twelve primary ZIKV immune sera from adults infected
5 to 38 months previously against a panel of 11 ZIKV isolates from the African, Asian and
American lineages. We assess the variability of neutralization potency of immune sera from
these subjects and the variability of susceptibility to neutralization for each virus isolate.
Overall, we found all sera neutralized all viruses at FRNT50 ranging from 1:271 to 1:4271, a
15.8-fold range, with only small differences between subject geometric mean titers (GMT)
against all viruses and small differences between each ZIKV isolate and sensitivity to neu-
tralization by all sera: when pooled, African strains were 1.3-fold more sensitive to neutrali-
zation by subject immune sera compared to pooled American strains. Finally, we subjected
our data to analysis using antigenic cartography, finding that ZIKV are highly antigenically
similar, with only a ~4-fold range across all antigenic distances between viruses, consistent
with a single serotype.
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Author summary
The recent emergence of Zika virus as an important human pathogen has raised questions
about the durability and breadth of Zika virus immunity following natural infection in
humans. While global epidemic patterns suggest that Zika infection elicits a protective
immune response that is likely to offer long-term protection against repeat infection by
other Zika viruses, only one study to date has formally examined the ability of human
Zika immune sera to neutralize different Zika viruses. That study was limited because it
evaluated human immune sera no more than 13 weeks after Zika virus infection and
tested a relatively small number of Zika viruses. In this study, we examine twelve human
Zika immune sera as far as 3 years after infection and test the sera against a total of eleven
Zika virus isolates. Our results confirm the earlier study and epidemic patterns that sug-
gest Zika virus exists in nature as a single serotype, and infection with one Zika virus can
be expected to elicit protective immunity against repeat infection by any Zika virus for
years to decades after the first infection.
Introduction
Although Zika virus (ZIKV) was first isolated in 1947 from a rhesus monkey in the Zika Forest
of Uganda[1, 2], only in the last decade has ZIKV emerged as a global public health threat. The
first large outbreak among humans was characterized by an epidemic of fever and rash on the
Island of Yap in 2007.[3, 4] ZIKV then went largely quiescent until introduction to French
Polynesia in 2013, where an epidemiologic association with Guillain-Barre´ syndrome (GBS)
was identified.[5] A rapid expansion ensued as ZIKV spread throughout Oceania, progressing
to the Americas in 2015.[6] Concern for the consequences of ZIKV infection heightened as an
increased number of infants born with microcephaly were recorded in areas of confirmed
ZIKV transmission in Brazil. The association between congenital abnormalities and GBS with
ZIKV infection prompted the World Health Organization (WHO) to declare a Public Health
Emergency of International Concern on February 1, 2016 (PHEIC).[7] Although ZIKV
remains a significant long-term public health challenge, on November 18, 2016, the WHO
announced that the ZIKV epidemic no longer met criteria for representing a PHEIC as the
number of reported cases decreased.
ZIKV is a single-stranded positive-sense RNA of the Flavivirus genus transmitted by Aedes
spp. mosquitoes. It has historically been assigned two major lineages, an African lineage and
an Asian lineage.[8] However, recent analyses suggest a third, American lineage, has emerged
from the Asian lineage.[9] The ZIKV virion contains three structural proteins: capsid (C), pre-
membrane/membrane(prM/M), and the envelope(E) glycoprotein. The E glycoprotein is the
primary target of virus-neutralizing antibodies following natural infection, and these antibod-
ies are thought to be primarily responsible for long-term protection against repeat infection.
[9] ZIKV E glycoproteins are highly conserved, with amino acid divergence at ~6% between
ZIKV lineages and ~2% within lineages. Phylogenetic analyses suggest that ZIKV exists as a
single serotype, however, significant differences in neutralization titers in dengue virus
(DENV) have been explained by as few as two amino acid substitutions,[10] and the amount
of amino acid variability needed to produce a distinct DENV serotype is difficult to predict.
[11]
Historically, immune sera raised in humans, mice, or non-human primates (NHP) have
been used to formally characterize flavivirus serotypes, with the first two DENV serotypes
being defined using five viruses isolates and four human convalescent immune sera[12]. What
PLOS NEGLECTED TROPICAL DISEASES Zika viruses form a single serotype
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0008006 April 13, 2020 2 / 15
IISR 2016-101586 (to W.B.M), and the Sunlin and
Priscilla Chou Foundation (to W.B.M.). The funders
had no role in study design, data collection and
analysis, decision to publish, or preparation of the
manuscript.
Competing interests: The authors have declared
that no competing interest exists.
we now know of as the four DENV serotypes were first defined using fourteen clinical virus
isolates, four NHP sera and an unreported number of mouse sera.[13] The original characteri-
zation of ZIKV as a distinct virus used a single ZIKV isolate and ZIKV immune sera from a
single NHP and sera from fourteen NHPs infected with other known sylvatic viruses [2]. How-
ever, the correlation between serotype-specific antibodies raised in experimentally infected
animals and human serotype-specific immunity following natural infection and has never
been established. To more fully characterize the potency and breadth of human ZIKV immune
sera many months to years after primary (single flavivirus) natural infection and empirically
evaluate the antigenic relationship between ZIKV, we tested a panel of twelve human sera col-
lected 5 to 38 months following ZIKV infection against eleven genetically distinct ZIKV iso-
lates. Immune sera potency and breadth were assessed using 50% focus reduction
neutralization tests (FRNT50) and we evaluated antigenic relatedness using antigenic cartogra-
phy. These study results confirm and advance the early work by others and have important
implications for ZIKV vaccine design and evaluation. Additionally they provide a solid basis
for estimating and understanding the very limited potential for antigenically variant ZIKV
viruses to penetrate otherwise ZIKV immune populations.
Methods
Human research ethics
The study has been reviewed and approved by the Oregon Health & Science University Institu-
tional Review Board (IRB#10212). Informed consent was obtained from subjects on initiation
of their participation in the study.
Study population
ZIKV immune individuals in this study were enrolled in a larger study of long-term immunity
following infection with the arthropod-borne DENVs, ZIKV, and chikungunya virus
(CHIKV). Prospective ZIKV study subjects were initially identified with the assistance of the
Oregon Health Authority (OHA) to whom the CDC reports PCR or serologically confirmed
ZIKV cases among Oregon residents. These individuals were invited to participate in the study
via US Postal Service mail. Subjects who contacted the long-term immunity study were offered
participation in the study, and following informed consent, provided additional history
including other known and suspected arboviral infections, lifetime travel histories, and yellow
fever virus (YFV) and Japanese encephalitis virus (JEV) vaccination histories.
Sample collection and storage
On enrollment, subjects provided approximately 80 mL of blood, with 30mL collected in BD
“red top” serum separator vacutainers (Becton-Dickson) for serologic studies and stored at
-80˚C until used for assays.
Viruses and tissue culture
All ZIKVs and yellow fever virus strain 17D (YFVax1) were propagated in C6/36 mosquito
cells (ATCC CRL 1660) in minimal essential media (MEM) supplemented with L-glutamine
(Gibco), non-essential amino acids (NEAA) (Gibco), antibiotic antimycotic (anti-anti)
(Gibco) and 5% by volume fetal bovine serum (FBS) incubated at 32˚C, 5% CO2. Zika viruses
included PRVABC59 (Puerto_Rico_2015) and FSS13025 (Cambodia_2010), both generously
provided by the World Reference Center for Emerging Viruses and Arboviruses (WRCEVA),
and ZIKV/Homo sapiens/COL/FLR/2015 (Colombia_2015), BeH819015 (Brazil_2015), MEX
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2–81 (Mexico_2016), 41525 (Senegal_1984), IbH_30656 (Nigeria_1968), and H/PF/2013
(French_Polynesia_2013), generously provided by Alec Hirsch, PhD, OHSU Vaccine and
Gene Therapy Institute. Strains MR766 (Uganda_1947), P 6–740 (Malaysia_1966), and
PLCal_ZV (Thailand, 2013) were obtained from BEI resources. 17D was obtained from the
manufacturer (Sanofi USA). DENV1, 3 and 4 were propagated in C6/36 cells as described
above. DENV2 was propagated in Vero cells that over-express furin (VF).[14, 15] VF cells
were grown in MEM with 10% FBS, NEAA, anti-anti, and selection antibiotic G418 (Invivo-
Gen) at 37˚C and 5% CO2 DENV used in neutralization assays included infectious clones of
DENV3 UNC3001,[16] and DENV4 DV4SL1992a[17] as well as DENV1 WestPac’74 (gener-
ously provided by Stephen Whitehead, National Institutes of Health) and DENV2 16803
(WRCEVA). All neutralization assays were performed using Vero cells (ATCC CCL-81) simi-
larly grown with MEM, NEAA, anti-anti and 10% by volume FBS incubated at 37˚C and 5%
CO2.
Neutralization assays
Fifty percent focus reduction neutralization test (FRNT50) titers were used to characterize sub-
ject sera. Subject sera were first heat-inactivated at 56˚C for 30 minutes. Sera were then diluted
four-fold in MEM supplemented with 2% FBS from a starting dilution of 1:10 and mixed with
an equal volume of ~100 focus forming units (FFU) of ZIKV strains giving a final starting dilu-
tion of 1:20. Virus-dilution mixes without sera were prepared simultaneously as controls for
input virus FFUs. After 1 hour of incubation, virus mixes were inoculated into individual wells
of 96 well plates seeded with Vero cells, incubated for 1 hour, and overlaid with 1% methylcel-
lulose in Opti-MEM (Gibco) supplemented with NEAA, anti-anti, amphotericin B, and 2%
FBS. Plates were incubated for 24 hours at 37˚C, 5% CO2. The overlay was then removed,
monolayers were fixed with 4% formaldehyde, incubated with the anti-flavivirus mouse mono-
clonal antibody (4G2) (ATCC HB 112) followed by a horse-radish peroxidase (HRP) conju-
gated secondary goat-anti-mouse antibody (ThermoFisher Scientific Cat # 62–6520). Plates
were washed 3 times with PBS and HRP True Blue Peroxidase Substrate (KPL) was then
applied for 15–60 minutes to visualize infected foci. Using a CTL ImmunoSpot instrument
(CTL, Cleveland, OH, USA), foci in individual wells were scanned, counted, and counts
underwent quality control. Proportion of virus neutralized per well was calculated and the
serum dilution that neutralizes 50% of control input virus (FRNT50) was determined by sig-
moidal dose-response curve fitting of percent neutralization vs. fold serum dilution using
GraphPad Prism1 (Version 7.0). All assays were performed in biologic duplicates. Individual
sera that showed a greater than 4-fold difference between biologic replicates were subjected to
repeat neutralization assays. Initial neutralization assays against DENV1-4 and YFV 17D were
conducted in a similar manner in a 24-well plate format with 30–40 PFU/well. DENV plates
were incubated for 5 days and counter stained for infectious foci in the same manner as
ZIKVs, 17D plates were incubated for 7 days and counter stained with crystal violet to visualize
infectious plaques. Fifty-percent neutralization titers for all assays are reported as the fold-
dilutions.
Antigenic cartography. The ZIKV antigenic map was constructed as previously
described[11, 18] and implemented using the Acmacs Web Cherry platform (https://acmacs-
web.antigenic-cartography.org/). Briefly, antigenic maps are constructed by first generating a
table of antigenic distances (Dij) between each individual virus (i) and serum (j) using serum
titers for each serum-titer pair (Nij). To calculate table distance, the titer against the best neu-
tralized virus for that serum is defined as bi and the distances for that serum are calculated as
Dij = log2(bi)-log(Nij). For the best neutralized virus for that serum, Nij = bi, and this distance
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will be equal to 0. For the remaining serum-virus pairs, table distance Dij is equivalent to the
fold-difference in titer between bij and Nij. Euclidean map distance (dij) for each serum-virus
pair is found by minimizing the error between the table distance Dij and map distance, dij,
using the error function E = ∑ije(Dij,dij), where e(Dij,dij) = (Dij-dij)2 when the neutralization
titer is above 1:20. For viruses with neutralization titers <1:20, the error was defined as e(Dij,
dij) = (Dij-1-dij)2(1/1+e-10(Dij-1-dij)) To make a map and derive dij for each serum-virus pair,
viruses and sera are assigned random starting coordinates and the error function is minimized
using the conjugate gradient optimization method. One thousand independent optimizations
were conducted to generate the aintgenic map.
Statistical analyses
The evolutionary history for the genetic relatedness of ZIKV was inferred by using the Maxi-
mum Likelihood method and General Time Reversible model. The tree with the highest log
likelihood was retained. Initial tree(s) for the heuristic search were obtained automatically by
applying Neighbor-Join and BioNJ algorithms to a matrix of pairwise distances estimated
using the Maximum Composite Likelihood (MCL) approach, and then selecting the topology
with superior log likelihood value. Codon positions included were 1st+2nd+3rd. There were a
total of 2382 positions in the final dataset. Evolutionary analyses were conducted in MEGA X.
[19]
Geometric mean titers between sera were plotted and compared in GraphPad Prism (Ver-
sion 8.00 for Mac, GraphPad Software, La Jolla California USA, www.graphpad.com) using
ANOVA followed by Bonferroni’s correction for multiple comparisons. Potency and breadth
survival curves were assembled in GraphPad Prism and compared using a Mantel-Cox non-
parametric comparison followed by Bonferroni’s correction for multiple comparisons
(adjusted P = 0.05). Correlation between geometric mean titer (GMT) or area under the curve
(AUC) for survival curves and months post-infection was assessed using standard least-squares
fitting of log10 transformed FRNT50 or AUC and months post-infection (power model) using
JMP1 (Version 14.0.0. SAS Institute Inc., Cary, NC, 1989–2019.)
Sequencing
Viral RNA was isolated from tissue culture supernatants using QIAamp Viral RNA Mini Kit
(Qiagen). cDNA was generated using random hexamers and SuperScript II Reverse Transcrip-
tase (Thermo Fisher), according to the manufacturer’s instructions. Capsid genes were ampli-
fied from cDNA using primers ZV_seqA_s and ZV_seqA_a using Phusion Polymerase
according to the manufacturer’s instructions. Fifty μL reactions (1X HF buffer (Thermo
Fisher), 200mM each dNTP, 0.5mM forward primer, 0.5mM reverse primer, 1U Phusion Poly-
merase and 4mL cDNA) were subjected to thermocycling conditions of 98˚C for 30 seconds,
followed by 40 cycles of 98˚C for 10 seconds, 58˚C for 15 seconds and 72˚C for 15 seconds,
prior to final extension at 72˚C for 10 minutes. prM, and E genes were amplified from cDNA
using primers ZV_seqB_s and ZVseqF_a and Phusion Polymerase as 50 μL reactions as before
(S1 Table). Thermocycling conditions consisted of 98˚C for 30 seconds, followed by 40 cycles
of 98˚C for 10 seconds, 55˚C for 15 seconds and 72˚C for 80 seconds, prior to final extension
at 72˚C for 10 minutes. PCR products were visualized on 1.5% agarose gel with ethidium bro-
mide, purified (QIAquick PCR Purification Kit, Qiagen) and mixed with sequencing primers
(S1 Table) for submission to a commercial sequencing company (Genewiz) for Sanger
sequencing. Contigs were assembled from chromatographs and aligned using Geneious Prime
(version 2019.2.1).
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Results
Study subjects
A total of 12 subjects with history of ZIKV infection (Table 1) and without serologic evidence
of DENV infection (Table 2) were identified. Clinical infections were documented between
February 2014 and December 2016 and individual subject sera were obtained anywhere from
5 to 38 months post-infection. Infections were primarily acquired in Latin America or the
Caribbean with two infections documented in the Cook Islands, five subjects had documented
yellow fever vaccinations, all of whom had detectable YFV neutralizing antibodies (Table 2).
Zika viruses. ZIKV immune sera from the 12 subjects were tested against eleven ZIKV
strains (Table 3): five of American lineage, three of Asian lineage, and three of African lineage.
Overall amino acid homology in the ZIKV structural proteins C/prM/E between these strains
range from 95.7–99.7% (mean: 98.2%). The viruses grouped by area of geographic isolation
with the French Polynesian isolate most closely related to the four Latin American isolates (Fig
1).
Virus specific neutralization by subject. We first evaluated individual serum neutralizing
potency against each of the eleven viruses (Fig 2). Individual FRNT50 values between sera ran-
ged from a serum dilution of 1:271 (serum 12462 vs Senegal_1968) to a serum dilution of
1:4271 (serum 14269 vs Malaysia_1966), a 15.8-fold range between all subjects and all viruses.
However, within subject variability was substantial less, ranging from 2.28-fold (subject 14278)
to 4.44-fold (subject 14236) (Fig 2). None of the titers showed significant differences within
subjects (ANOVA).
Between subject serum potency and breadth. We next compared geometric mean titers
between each subject (Fig 3A) by ANOVA and overall potency and breadth by survival curve
analysis (Fig 3B). Overall, individual subject GMT against all eleven viruses had a relatively
narrow range, from a low of 1:521(subject 12462) to a high of 1:2020 (subject 14269), or a
3.9-fold difference. Subject 12462 serum GMT was significantly lower than all other subject
sera, subject 11981 had a significantly lower GMT (1:990) against 4 subject sera, and subject
14269 had a significantly higher GMT against 5 other subject sera (ANOVA followed by
Tukey HSD, Fig 3A). As an alternate approach to visualizing and comparing individual subject
neutralization profiles, we constructed potency and breadth curves for each subject (Fig 3B).
Table 1. Study subjects.
ID Sex Age Country of infection Months post-infection Year received yellow fever vaccine
11884 Male 28 Nicaragua 5 NV
14269 Female 45 Cuba 10 NV
14278 Female 51 Mexico 10 NV
14276 Female 52 Virgin Islands 12 NV
14252 Female 24 Mexico 13 2013
14664 Female 39 Jamaica 14 2002
11981 Female 44 Dominican Republic 15 2008
14236 Male 55 Nicaragua 15 1997
14137 Female 41 Guatemala 18 2003
12451 Female 61 Cook Islands 24 NV
12462 Male 69 Cook Islands 27 NV
11942 Female 25 Haiti 38 NV
NV = Not Vaccinated
https://doi.org/10.1371/journal.pntd.0008006.t001
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Potency and breadth neutralization curves were first developed in the HIV field to characterize
broadly neutralizing antibodies and immune sera against panels of HIV pseudoviruses (de
Camp et al, 2014). These curves maintain resolution at the level of neutralization titer against
each virus, rather than calculating a mean estimate based on all titers. Curves show the number
of viruses neutralized at a given serum dilution over the range of all dilutions tested, analogous
to survival over time in a Kaplan-Meier curve. Curves are compared using the non-parametric
Mantel-Cox test followed by a Bonferroni correction for multiple comparisons. This approach
does not assume a normal distribution of individual titers, but is also less sensitive to differ-
ences between curves. Upon inspection, 12462 again stands out as different from all other sub-
jects’ neutralization pattern, although the difference was only statistically significant for sera
14278, 14252, 14236, 11981, 12451 and 11942. None of the other eleven sera tested differed
from one-another in potency or breadth. Finally, we tested whether there was a correlation
between GMT (Fig 3A) or area under the curve (Fig 3B) and months post-infection, finding
no correlation between time since infection and subsequent ZIKV neutralizing antibody titers
(adjusted R2 = -0.1, P = 0.80 for both GMT and AUC).
Table 2. Subject neutralization profiles by fold serum dilution yielding 50% neutralization (FRNT50).
ID ZIKV DENV1 DENV2 DENV3 DENV4 YFV
11884 586 <20 <20 <20 <20 <20
14269 1480 <20 <20 <20 <20 <20
14278 1037 <20 <20 <20 <20 <20
14276 1046 <20 <20 <20 <20 <20
14252 2120 <20 <20 <20 <20 159
14664 1164 <20 <20 <20 <20 695
11981 1409 <20 <20 <20 <20 22
14236 2108 <20 <20 <20 <20 180
14137 637 <20 <20 <20 <20 378
12451 895 <20 <20 <20 <20 <20
12462 932 <20 <20 <20 <20 <20
11942 610 <20 <20 <20 <20 <20
ZIKV = Peurto_Rico_2015
https://doi.org/10.1371/journal.pntd.0008006.t002
Table 3.
Virus strain name Isolate Accession # Year isolated Location
Uganda_1947 MR766 MN755624 1947 Uganda
Senegal_1984 41525 MN755616 1984 Senegal
Nigeria_1968 IbH_30656 MN755617 1968 Nigeria
Malaysia_1966 P 6–740 MN755625 1966 Malaysia
Cambodia_2010 FSS13025 MN755621 2010 Cambodia
Thailand_2013 PLCal_ZV MN755626 2013 Thailand
French_Polynesia_2013 H/PF/2013 MN755619 2013 French Polynesia
Puerto_Rico_2015 PRVABC59 MN755623 2015 Puerto Rico
Brazil_2015 BeH819015 MN755622 2015 Brazil
Colombia_2015 ZIKV/Homo sapiens/COL/FLR/2015 MN755620 2015 Colombia
Mexico_2016 MEX 2–81 MN755618 2016 Mexico
https://doi.org/10.1371/journal.pntd.0008006.t003
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Neutralization by virus and antigenic cartography. To specifically address the relative
differences in virus sensitivity to neutralization by human immune sera, we first compared
GMTs for each virus against all sera (Fig 4A). GMTs for each virus ranged from 1:836 for
French_Poly_2013 to 1:1594 for Nigeria_1968, a 1.91-fold difference. None of the differences
between any of the GMTs by virus were statistically significant (ANOVA followed by Tukey
HSD post-hoc test). When comparted by strain, the GMTs for African, Asian, and American
were 1:1400, 1:1306, and 1:1067, respectively, with the African and the American strains differ-
ing significantly from one another, a 1.31-fold difference (ANOVA followed by Bonferroni,
P = 0.016).
To further characterize the antigenic relationship between genetically distinct ZIKV, we
turned to antigenic cartography.[11, 18] Antigenic cartography has been implemented previ-
ously to describe the antigenic relatedness of dengue viruses[11, 20] and influenza.[18, 21–23]
Antigenic maps offer an alternate way to evaluate neutralization titers in that they are based on
neutralization data that reflect the antigenic rather than genetic relatedness of pathogens. Viral
antigenic maps fit neutralization titers for all sera against all viruses simultaneously: each virus
is measured in relation to many immune sera, allowing for a more accurate estimate of anti-
genic relatedness than that which is provided by individual neutralization titers. Antigenically,
ZIKV formed a discrete and compact map, with the greatest antigenic unit (AU) distances no
greater than ~four-fold range across the two-dimensional map space (Fig 5), equivalent to a
single dilution in the FRNT assay used to estimate FRNT50 values for this map. The two Afri-
can strains mapped to nearly identical loci, while the American strains were located at rela-
tively larger, but still quite small, antigenic distances from one another, while the lone Asian
strain in our panel was centrally located among the American and African strains. Compared
Fig 1. Molecular phylogenetic analysis by maximum likelihood method. The percentage of trees in which the
associated taxa clustered together is shown next to the branches. The tree is drawn to scale, with branch lengths
measured in the number of substitutions per site. Colored bars correspond to virus strain region of isolation.
https://doi.org/10.1371/journal.pntd.0008006.g001
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to the dengue viruses, ZIKV were more tightly clustered and more closely related antigenically
than DENV viruses are when mapped using human primary DENV immune sera.[11]
Discussion
Phylogenetic comparisons between historic and contemporary ZIKV isolates find minimal
genetic variability, supporting the generally held hypothesis that ZIKVs antigenically form a
single serotype.[9] However, within flaviviruses it has been shown that relatively few genetic—
amino acid encoding—differences can be associated with significant differences in virus sus-
ceptibility to neutralization by human immune sera raised against otherwise genetically very
similar viruses.[10, 16, 24] Consequently, the antigenic differences between closely related fla-
viviruses cannot be inferred by genetic analysis alone, and empiric characterization of closely
related viruses using serologic assays is still necessary to validate assumptions about antigen
relationships within genetically similar flaviviruses. Ideally, this characterization should be
undertaken with a set of viruses that capture within virus genetic diversity and a set of sera
from individuals with diverse exposure histories to the same group of genetically similar
viruses. To date, only one study, Dowd et al.,[25] has examined the serotype specificity of con-
temporary human ZIKV convalescent immune sera from the most recent 2014–2016 epidemic
against the three genetically distinct ZIKV strains. While Dowd et al. was a critically important
first approximation of the potency and breadth of human ZIKV-specific immune sera follow-
ing natural infection, the study had several limitations: only three ZIKV strains were fully
Fig 2. FRNT50 titers for subject sera against each virus. Fold serum dilution is shown on the left Y-axis, geometric mean titer (GMT) for each subject against
all 11 viruses is plotted on the right Y-axis. Viruses and their relative phylogenetic relationships are shown on the X-axis. Subject age, gender, country infection
acquired, months post-infection and fold-FRNT50 range are reported above each serum plot. The sera are ordered left to right from most recent to most remote
infection.
https://doi.org/10.1371/journal.pntd.0008006.g002
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evaluated against eight ZIKV-confirmed human convalescent sera; the convalescent sera were
collected in an early convalescent time period 3 to 12.6 weeks post infection, when short-lived
flavivirus cross-reactive IgM and IgG titers are expected to be high,[26, 27] and, finally, subject
co-existent flavivirus immunity to DENV or other flaviviruses in the human subjects was not
assessed. Here we conducted an in-depth analysis of a panel of genetically similar but distinct
ZIKV against a panel of primary ZIKV-immune sera from individuals infected 5–38 months
prior these immunologic studies. Our work builds upon and expands earlier results reported
by Dowd et al.[25] which was limited to nine early convalescent ZIKV immune sera (<3
months) and only three ZIKV isolates. All subject sera in our study potently neutralized all
ZIKV isolates at FRNT50 >1:320 (Fig 2), and although the GMT against all viruses for one sub-
ject, 12462, was significantly lower compared to the GMTs for the other eleven subjects (Fig
3A), this may reflect a host factor such as subject age at infection– 70 years old–rather than an
underlying immunogenic difference between the infecting viruses. The identity of the infecting
virus is not known, but can be reasonably assumed to be an American strain (infected in the
Cook Islands in 2014), and another subject, 18451, was infected at the same time and location
as subject 12462, presumably with the same virus strain, but did not develop lower immune
titers. We did not observe any trends towards a relationship between time post-infection, geo-
graphic location of infection, and specificity, breadth, or potency of immune sera titers.
When FRNT50 titers were compared by virus (Fig 4A), none of the viruses differed in their
GMT against the twelve subject sera. However, it is interesting to note that, when pooled by strain,
we did find a statistically significant, but small, 1.4-fold difference between GMT for both African
Fig 3. Potency and breadth of subject immune sera. A) GMT for each serum against eleven ZIKV isolates. Y-axis shows fold-serum dilution, each virus
FNRT50 value is plotted by the correlating symbol show in the legend below the plot. The symbols are color coded to match the sera indicated in Fig 2. Line
and whiskers show serum GMT and 95% confidence. The GMT for subject 12462 (�) was significantly lower than all other sera (ANOVA followed by Tukey’s
correction for multiple comparisons, P<0.05). Remaining sera pairs that had GMTs that differed significantly are show by horizontal bars (ANOVA followed
by Tukey’s correction for multiple comparisons, P<0.05) B) Potency and breadth curve for each subject serum. The Y-axes shows proportion of viruses
neutralized (N = 11), X axis shows fold serum dilution. The plots are color coded to match the sera in Fig 2. The plot for each serum shows the proportion of
viruses neutralized by FRNT50 at a given serum dilution. Each step in each plot represents an FRNT50 value for one virus; as fold serum dilution increases for
each serum, the proportion of viruses neutralized decreases by 1/11 (9.1%) as each FRNT50 dilution for each virus is crossed.
�differs from 12462, Mantel-Cox
followed by Bonferroni’s correction for multiple comparisons, P<0.05.
https://doi.org/10.1371/journal.pntd.0008006.g003
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strains compared to the five American strains. These two strains have 8 conserved amino acid dif-
ferences across the E glycoprotein (Supplemental Table), four of which are predicted to be surface-
Fig 4. Neutralization by virus and strain. A) FRNT50 titers for each serum against each virus. The Y-axis shows fold-serum dilution, the X-axis
shows each virus, the phylogenetic tree below the X-axis shows the relative genetic relatedness of the viruses. Individual virus symbols are
indicated below the figure and the symbols are color-coded to match the sera in Fig 2. B) FRNT50 titers for ZIKV grouped by strain. Strain pairs
found to be different by ANOVA followed by Tukey HSD correction for multiple comparisons are show by brackets (P = 0.038).
https://doi.org/10.1371/journal.pntd.0008006.g004
Fig 5. Antigenic map of eleven ZIKVs against twelve human ZIKV immune sera from 5 to 38 months post-infection. Locator map shows the relative antigenic
relatedness between ZIKV and the dengue viruses. Each unit of antigenic distance (AU), the length of one side of a grid square, is equivalent to a two-fold dilution in the
neutralization assay. Inset map shows each serum and ZIKV. Sera are shown as open blobs colored to match each serum as in Fig 2. Each virus is shown as a filled blob
and is colored according to virus strain (American = slate blue, African = turquoise, Asian = steel blue). The size and shape of each blob is the confidence area of its
position. Dashed line circle has a diameter equal to 2 AU or four-fold, the difference of a single dilution in the FRNT assay used to estimate FRNT50 titer.
https://doi.org/10.1371/journal.pntd.0008006.g005
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exposed: T120A, located on the E domain II (EDII) d-e loop; V169I, located on the EDI F0 strand;
V317I, located on the EDIII A strand; and D393E, located on the EDIII f-g loop, part of the EDIII
lateral ridge epitope region. While it is beyond the scope of this research to evaluate whether these
residues contribute to the small but robust differences in neutralization between the African and
American ZIKV strains, all four regions have been implicated as targets for human ZIKV [28] and
DENV neutralizing mAbs.[29–31] Even so, the overall magnitude of neutralization potency across
all strains and sera suggests these differences are unlikely to play a meaningful role in antigenic
escape in the context of existing primary ZIKV immunity.
Analysis of our data by antigenic cartography provided similar results, with some notable
differences. While comparison of GMTs across titers and sera suggested some differences
between sera and titers in pairwise comparisons, when plotted using all serum-virus pairs
simultaneously, the resulting antigenic map is remarkably tight and homogeneous, with nei-
ther African or American strains grouping apart from the other strains, and while two African
strains were the closest to one another by antigenic distance, the antigenic map distances
between the African strains and the American strains are no greater than the antigenic map
distances with the American strains. Overall, the antigenic distance spanned by all viruses was
just over 2 AU, or four-fold, the difference of a single dilution in our FRNT assay, strongly sup-
porting the hypothesis that ZIKV constitutes a single serotype.
Although our results add significantly to our understanding of the potency and breadth of
antibodies elicited by primary ZIKV infection and the antigenic relationship between geneti-
cally distinct ZIKV, our study had several weaknesses: the virus strain(s) that infected our
study subjects has been inferred to be American strains by epidemic association rather than
virus isolation, and subjects with history of primary ZIKV infection by African or Asia strains
were not identified; our panel of viruses was biased towards recent American strain isolates,
with only three Asian and three African strains represented; and, the study is cross-sectional
and still only examines potency and breadth of immune sera through 3 years post-infection,
true “long-term” immunity, and longitudinal ZIKV immunity in study subjects was not exam-
ined. Future studies that address these weaknesses would substantially add to our understand-
ing of the natural history of ZIKV immunity in human populations, the limited role antibody
neutralization escape may play in ZIKV evolution, and the potential for ZIKV vaccines cur-
rently under development to protect against likely future genetic ZIKV variants.
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